CN115998740A - 毛发过度脱落的检测和治疗 - Google Patents

毛发过度脱落的检测和治疗 Download PDF

Info

Publication number
CN115998740A
CN115998740A CN202310057359.1A CN202310057359A CN115998740A CN 115998740 A CN115998740 A CN 115998740A CN 202310057359 A CN202310057359 A CN 202310057359A CN 115998740 A CN115998740 A CN 115998740A
Authority
CN
China
Prior art keywords
range
approximately
minoxidil
hair loss
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310057359.1A
Other languages
English (en)
Chinese (zh)
Inventor
罗德尼·辛克莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samson Clinical Pty Ltd
Original Assignee
Samson Clinical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55856287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115998740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014904327A external-priority patent/AU2014904327A0/en
Application filed by Samson Clinical Pty Ltd filed Critical Samson Clinical Pty Ltd
Publication of CN115998740A publication Critical patent/CN115998740A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202310057359.1A 2014-10-29 2015-10-29 毛发过度脱落的检测和治疗 Pending CN115998740A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2014904327 2014-10-29
AU2014904327A AU2014904327A0 (en) 2014-10-29 Detection and treatment of excessive hair shedding
CN201580061561.5A CN107106560A (zh) 2014-10-29 2015-10-29 毛发过度脱落的检测和治疗
PCT/AU2015/050682 WO2016065426A1 (en) 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580061561.5A Division CN107106560A (zh) 2014-10-29 2015-10-29 毛发过度脱落的检测和治疗

Publications (1)

Publication Number Publication Date
CN115998740A true CN115998740A (zh) 2023-04-25

Family

ID=55856287

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310057359.1A Pending CN115998740A (zh) 2014-10-29 2015-10-29 毛发过度脱落的检测和治疗
CN201580061561.5A Pending CN107106560A (zh) 2014-10-29 2015-10-29 毛发过度脱落的检测和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580061561.5A Pending CN107106560A (zh) 2014-10-29 2015-10-29 毛发过度脱落的检测和治疗

Country Status (11)

Country Link
US (2) US10226462B2 (cg-RX-API-DMAC10.html)
EP (2) EP3212192B1 (cg-RX-API-DMAC10.html)
JP (2) JP6915946B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240011239A (cg-RX-API-DMAC10.html)
CN (2) CN115998740A (cg-RX-API-DMAC10.html)
AU (4) AU2015337807B2 (cg-RX-API-DMAC10.html)
CA (2) CA3209849A1 (cg-RX-API-DMAC10.html)
ES (2) ES2773467T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ732075A (cg-RX-API-DMAC10.html)
SG (2) SG10202002705YA (cg-RX-API-DMAC10.html)
WO (1) WO2016065426A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20180189976A1 (en) 2016-12-29 2018-07-05 Michal Kasprzak Analysis unit and system for assessment of hair condition
KR20240064747A (ko) * 2017-07-12 2024-05-13 삼손 클리니컬 피티와이 엘티디 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN109674762A (zh) * 2019-03-05 2019-04-26 南京正大天晴制药有限公司 一种度他雄胺及治疗脱发的组合物胶囊
CN110478450B (zh) * 2019-10-09 2021-04-13 北海鑫臻药业有限公司 一种治疗阿尔茨海默病的药物组合物及其应用
CN111110721A (zh) * 2020-01-19 2020-05-08 朱炜 一种毛发防脱再生的复合制剂及其使用方法
JP7291908B2 (ja) * 2020-02-27 2023-06-16 パナソニックＩｐマネジメント株式会社 画像処理装置及び画像処理方法
WO2023055740A1 (en) * 2021-09-29 2023-04-06 Nirmana Bio, Inc. Hair loss therapy
US11744788B2 (en) * 2021-10-27 2023-09-05 James D. Welch Method of encouraging growth and regrowth of hair in human males technical area
US12667526B1 (en) * 2021-10-27 2026-06-30 James D. Welch Method of encouraging growth and regrowth of hair in human males
KR20250100660A (ko) 2022-10-25 2025-07-03 베라더믹스 인코포레이티드 변형 방출 미녹시딜의 조성물 및 사용 방법
EP4539816A4 (en) * 2023-09-01 2025-07-23 Follea Int COMPOSITIONS AND METHODS FOR AN ORALLY ADMINISTERED MINOXIDIL SUPPLEMENT FOR THE TREATMENT OF ALOPECIA
US20250213594A1 (en) * 2023-12-27 2025-07-03 Inventage Lab Inc. Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride
WO2026106796A1 (en) * 2024-11-18 2026-05-21 Follea International System and method for the treatment of telogen effluvium, androgenetic alopecia, and other hair loss disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011100917A4 (en) * 2011-07-26 2011-09-01 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
CN104053782A (zh) * 2011-09-26 2014-09-17 富力国际有限公司 用于预测对用于治疗雄激素性脱发的米诺地尔的反应的系统和方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
EP0557301B1 (en) * 1990-11-14 1995-03-22 The Upjohn Company 5-fluoro-2,4,6-pyrimidinetriamine compounds for preventing hair loss
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
GB2314019B (en) 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
WO1999040898A2 (en) 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
JP2000038340A (ja) 1998-05-20 2000-02-08 Kumahiro Miyama 育毛剤および食品
JP2003012542A (ja) 2001-06-26 2003-01-15 Toray Ind Inc 発毛促進剤
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CN1838969A (zh) 2004-10-07 2006-09-27 三仪股份有限公司 经皮和经粘膜制剂
US20080064765A1 (en) 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
US8110655B2 (en) * 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
EP2344198B1 (en) 2008-09-27 2020-11-04 Jina Pharmaceuticals Inc. Lipid based pharmaceutical preparations for topical application
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
WO2013181487A2 (en) 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US9561224B1 (en) 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia
KR20240064747A (ko) 2017-07-12 2024-05-13 삼손 클리니컬 피티와이 엘티디 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011100917A4 (en) * 2011-07-26 2011-09-01 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
CN104053782A (zh) * 2011-09-26 2014-09-17 富力国际有限公司 用于预测对用于治疗雄激素性脱发的米诺地尔的反应的系统和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张菊芳: "《毛发整形美容学》", 28 February 2013, 浙江科学技术出版社, pages: 60 - 61 *
曹春林主编: "《中药药剂学》", 30 November 1986, 上海：上海科学技术出版社, pages: 527 - 528 *

Also Published As

Publication number Publication date
CN107106560A (zh) 2017-08-29
CA3209849A1 (en) 2016-05-06
KR20240011239A (ko) 2024-01-25
CA3003940C (en) 2023-10-10
WO2016065426A1 (en) 2016-05-06
US11116770B2 (en) 2021-09-14
AU2017210523B2 (en) 2018-11-15
EP3626244A1 (en) 2020-03-25
JP2020109127A (ja) 2020-07-16
US20170333432A1 (en) 2017-11-23
CA3003940A1 (en) 2016-05-06
SG11201703424WA (en) 2017-05-30
SG10202002705YA (en) 2020-05-28
EP3626244B1 (en) 2023-06-07
AU2020203695B2 (en) 2021-09-02
AU2017210523A1 (en) 2017-08-17
EP3212192A4 (en) 2018-07-04
KR20170102214A (ko) 2017-09-08
US10226462B2 (en) 2019-03-12
AU2018279055A1 (en) 2019-01-17
EP3212192A1 (en) 2017-09-06
ES2773467T3 (es) 2020-07-13
ES2952159T3 (es) 2023-10-27
AU2020203695A1 (en) 2020-06-25
NZ732075A (en) 2022-09-30
AU2015337807A1 (en) 2017-04-13
JP2017533265A (ja) 2017-11-09
JP6915946B2 (ja) 2021-08-11
KR102625061B1 (ko) 2024-01-16
US20190192513A1 (en) 2019-06-27
EP3212192B1 (en) 2019-11-20
AU2015337807B2 (en) 2017-05-04
HK1243641A1 (en) 2018-07-20

Similar Documents

Publication Publication Date Title
AU2020203695B2 (en) Detection and treatment of excessive hair shedding
Singal et al. Female pattern hair loss
US20250064807A1 (en) Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding
JP2004500353A (ja) アンドロゲン性およびび慢性脱毛症の治療のためのメラトニンの使用
RU2431485C2 (ru) Способ лечения нарушений роста волос, таких как облысение по женскому типу, и применяемые в нем композиции
Sinclair et al. Fast facts: disorders of the hair and scalp
HK40023042A (en) Oral minoxidil for the treatment of alopecia areata
Billewicz et al. Skin appendage abnormalities in hypothyroidism: understanding and management
HK40023042B (en) Oral minoxidil for the treatment of alopecia areata
HK1243641B (en) Oral minoxidil for the treatment of telogen effluvium
Piraccini et al. Effectiveness and Safety of Topical Finasteride for Male Androgenetic Alopecia: Real World Data
Rebora Changes in Growth and Distribution of Hair Associated with Psychotropic Drug Use: Incidence and Mechanisms
Katoulis et al. Frontal fibrosing alopecia
Hamzeh et al. Common Causes of Hair Loss
WO2025055906A1 (zh) 吡咯并嘧啶类化合物的用途及其组合物
de Oliveira Community Pharmacy and Hospital Pharmacy Internship Reports and Monograph" Counseling for Androgenetic Alopecia-The Pharmacist's Role"
IL308737A (en) A formulation for treating and preventing hair loss
Lindholm Assessing the safety profile of a new antihypertensive agent
Thuangtong Common Alopecia
Adikrishnan et al. Murugan S, Mahalakshmi V, Anandan S, Sudha R Department of Dermatology, Sri Ramachandra University, Chennai, India Introduction: Kerion is an inflammatory type of tinea capitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination